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Abstract
The risk of ischemic events gradually decreases after acute coronary syndrome (ACS), reaching a stable 
level after 1 month, while the risk of bleeding remains steady during the whole period of dual antiplatelet 
treatment (DAPT). Several de-escalation strategies of antiplatelet treatment aiming to enhance safety of 
DAPT without depriving it of its efficacy have been evaluated so far. 
We hypothesized that reduction of the ticagrelor maintenance dose 1 month after ACS and its continua-
tion until 12 months after ACS may improve adherence to antiplatelet treatment due to better tolerability 
compared with the standard dose of ticagrelor. Moreover, improved safety of treatment and preserved 
anti-ischemic benefit may also be expected with additional acetylsalicylic acid (ASA) withdrawal. To 
evaluate these hypotheses, we designed the Evaluating Safety and Efficacy of Two Ticagrelor-based  
De-escalation Antiplatelet Strategies in Acute Coronary Syndrome — a randomized clinical trial 
(ELECTRA-SIRIO 2), to assess the influence of ticagrelor dose reduction with or without continuation 
of ASA versus DAPT with standard dose ticagrelor in reducing clinically relevant bleeding and main-
taining anti-ischemic efficacy in ACS patients. 
The study was designed as a phase III, randomized, multicenter, double-blind, investigator-initiated 
clinical study with a 12-month follow-up (ClinicalTrials.gov Identifier: NCT04718025; EudraCT 
number: 2020-005130-15). (Cardiol J 2021; 28, 4: 607–614)
Key words: acute coronary syndrome, ticagrelor, antiplatelet therapy, de-escalation, 
ELECTRA-SIRIO 2
Introduction
Elevated rates of ischemic events cluster-
ing during the first month after acute coronary 
syndrome (ACS) is reflective of elevated platelet 
reactivity during this period. The risk of major 
adverse cardiovascular events (MACE), including 
cardiovascular death, myocardial infarction (MI), 
and stroke, gradually decreases, reaching a stable 
level after 1 month, while the risk of bleeding is 
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mainly related to the type and dosage of antiplatelet 
drugs and remains steady during the whole period 
of dual antiplatelet treatment (DAPT). Therefore, 
in the earliest phase after ACS, the ischemic 
component should be especially targeted with 
potent antiplatelet strategies, whereas after the 
clinical stabilization occurs, de-escalation of the 
antiplatelet therapy may be justified [1–8]. Treat-
ment with ticagrelor or prasugrel is recommended 
over clopidogrel due to better efficacy, albeit 
with more bleeding complications. These higher 
bleeding rates have provoked trials investigat-
ing de-escalation from ticagrelor or prasugrel to 
clopidogrel in the hope of reducing bleeding with-
out increasing rates of thrombotic events [4, 5]. 
Several strategies aiming to enhance the safety of 
antiplatelet treatment without depriving it of its 
efficacy have been evaluated so far.
Replacing a potent P2Y12 receptor inhibitor 
(prasugrel or ticagrelor) with a weaker one (clopi-
dogrel) was the first de-escalation strategy tested. 
In the TOPIC study downgrading of DAPT (from 
prasugrel or ticagrelor to clopidogrel) 1 month af-
ter ACS was associated with a net clinical benefit 
mainly driven by a significant reduction in bleeding 
complications, while the risk of recurrent ischemic 
events remained unchanged [9]. The limitations of 
this study, including small study sample size (645 
patients), non-homogenous treatment at baseline 
and in the control arm (prasugrel or ticagrelor), and 
moderate adherence to the treatment, warrant cau-
tious interpretation of these results. On the other 
hand, the SCOPE registry (n = 1363) reported 
switching from clopidogrel to novel P2Y12 recep-
tor inhibitors to be safe, while a downgrade was an 
independent predictor of net adverse cerebrovas-
cular events in patients with ACS [10]. The safety 
and efficacy of early de-escalation of antiplatelet 
treatment from prasugrel to clopidogrel were 
tested in the TROPICAL-ACS study (n = 2610) 
[11]. High platelet reactivity is associated with an 
increased risk of recurrent ischemic events, while 
the use of clopidogrel is burdened with high inter-
individual variability of the antiplatelet effect and 
the possibility of drug interactions [12]. Hence, 
platelet function testing was applied for guidance 
of de-escalation of antiplatelet treatment in this 
study. In the de-escalation group as much as 39% 
of patients required a switch-back to prasugrel due 
to insufficient platelet inhibition with clopidogrel 
defined as high platelet reactivity [11]. The primary 
endpoint, defined as net clinical benefit (cardio-
vascular death, MI, stroke, or bleeding grade 2 or 
higher according to Bleeding Academic Research 
Consortium [BARC] criteria) 1 year after randomi-
zation, occurred in 7% of patients in the guided de-
escalation group and in 9% of patients in the control 
group (pnon-inferiority = 0.0004; hazard ratio [HR] 0.81; 
95% confidence interval [CI] 0.62–1.06, psuperiority 
= 0.12). The prevalence of ischemic events (car-
diovascular death, MI, and stroke) was 3% in both 
study arms, while the prevalence of BARC grade 2 
or higher was 5% and 6%, respectively. Despite 
of the lack of significant differences in the whole 
study population, subgroup analyses revealed 
a net clinical benefit from guided de-escalation in 
ST-segment elevation MI patients, subjects ≤ 70 
years of age, and those without diabetes. Summing 
up, this investigator-initiated, randomized, open-
-label, assessor-blinded, multicenter trial showed 
that platelet function testing-guided de-escalation 
from prasugrel to clopidogrel was non-inferior to 
standard treatment with prasugrel at 1 year after 
percutaneous coronary intervention (PCI) in terms 
of net clinical benefit in patients with ACS [11]. 
Kheiri et al. [13] conducted a meta-analysis 
(3 randomized clinical trials with 3391 patients) 
aimed at evaluating the clinical outcomes of an-
tiplatelet de-escalation based on switching from 
prasugrel or ticagrelor to clopidogrel compared 
with continuation of DAPT with more potent P2Y12 
receptor inhibitor in patients treated with PCI. 
The net clinical outcome (composite of bleeding or 
thrombotic events) was significantly reduced in the 
group switched to clopidogrel; however, no differ-
ences between the groups in a separate analysis for 
MACE, as well as for bleedings, were found [13].
Pharmacodynamic data show that reduction of 
ticagrelor bioavailability by one-third significantly 
decreases the antiplatelet effect of ticagrelor in 
patients with acute MI, but not in subjects without 
ACS [14–16]. More pronounced ticagrelor-induced 
platelet inhibition seen in a stable setting compared 
with MI reflects the excessive platelet activation 
occurring during the initial phase of ACS. Subse-
quently, the enhanced platelet reactivity and ag-
gregation decrease over time when ACS patients 
become stable [17–22]. This observation was 
confirmed in a sub-study of the PEGASUS-TIMI 
54 trial showing similar platelet inhibition with 
reduced (60 mg b.i.d) and standard (90 mg b.i.d) 
maintenance doses in stable patients more than 
1 year after MI, despite one-third lower ticagre-
lor plasma concentrations in the lower dose arm 
[23–25]. Recently, we demonstrated in a rand-
omized, pharmacodynamic trial that a reduced tica-
grelor maintenance dose of 60 mg b.i.d. provides 
a comparable antiplatelet effect to the standard 
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90 mg b.i.d. dose in patients already 1 month post 
MI, when the disease proceeds to its stable phase. 
Importantly, no differences in the prevalence of 
on-ticagrelor high platelet reactivity between 
patients receiving the reduced and standard main-
tenance doses was observed in this trial [26, 27]. 
The number of studies reporting clinical out-
comes in coronary artery disease patients receiving 
reduced maintenance dose of ticagrelor is limited; 
however, available results indicate that in a stable 
setting this strategy offers improved safety with 
preserved efficacy in the prevention of thrombotic 
events [7]. The PEGASUS-TIMI 54 study showed 
comparable clinical efficacy of two ticagrelor doses 
(90 mg b.i.d. and 60 mg b.i.d.) administered with 
acetylsalicylic acid (ASA); however, better tol-
erability of treatment with the lower dose was 
observed in stable patients 1 year after MI [23]. 
Another strategy to optimize antiplatelet treat-
ment, by adjusting its potency to time-changing 
required platelet inhibition, has been validated in 
the TWILIGHT study [28]. The primary endpoint 
was the first occurrence of BARC type 2, 3, or 
5 bleeding between randomization and 1 year in 
a time-to-event analysis. The key secondary end-
point was the first occurrence of death from any 
cause, nonfatal MI, or nonfatal stroke in a time-to- 
-event analysis. The results of this randomized trial 
showed that in 7119 high-risk patients who had 
undergone PCI and were treated with ticagrelor 
90 mg b.i.d. and ASA for 3 months, subsequent 
monotherapy with ticagrelor resulted in substan-
tially fewer bleeding events than in the ticagrelor 
plus ASA arm (4.0% vs. 7.1%, respectively; HR 
0.56; 95% CI 0.45–0.68; p < 0.001), without any 
ischemic harm over a period of 1 year; the key 
secondary endpoint occurred in 3.9% of patients 
in both study arms [28]. Even in high-risk patients 
after complex PCI, the DAPT downgrade to tica-
grelor monotherapy was associated with lower 
incidence of bleeding without increased risk of 
ischemic events compared with continuation of 
DAPT [29, 30]. 
Khan et al. [31] performed a Bayesian network 
meta-analysis comparing early de-escalation of 
DAPT (1–3 months) to monotherapy with either 
P2Y12 inhibitor or ASA versus 12 months de-
escalation of DAPT after PCI with drug-eluting 
stent. Among the 7 trials included (35,821 pa-
tients), 52.6% of patients presented with ACS. 
No significant differences in terms of ischemic 
endpoints among different DAPT strategies were 
found; however, early de-escalation of DAPT to 
monotherapy with a P2Y12 inhibitor instead of 
ASA might be a safer approach compared with 12 
months of DAPT in patients treated with PCI [31].
Taking into account these data, we hypoth-
esized that reduction of ticagrelor maintenance 
dose to 60 mg b.i.d. 1 month after ACS and its con-
tinuation until 12 months may improve adherence 
to antiplatelet treatment due to better tolerability 
compared with DAPT including standard dose tica-
grelor. Moreover, based on the TWILIGHT study 
results [29], improved safety of treatment and pre-
served anti-ischemic benefit with additional ASA 
withdrawal may also be expected. To evaluate these 
hypotheses, we designed the Evaluating Safety and 
Efficacy of Two Ticagrelor-based De-escalation An-
tiplatelet Strategies in Acute Coronary Syndrome 
— a randomized clinical trial (ELECTRA-SIRIO 2), 
to assess the influence of ticagrelor dose reduction 
with or without continuation of ASA versus DAPT 
with standard-dose ticagrelor in reducing clinically 
relevant bleeding and maintaining anti-ischemic 
efficacy in ACS patients. 
Current standard of treatment  
according to the guidelines
In ACS patients DAPT with a P2Y12 recep-
tor inhibitor on top of ASA is recommended for 12 
months to reduce platelet reactivity and adverse 
thrombotic events (class of recommendation I) 
[1, 2, 4]. However, in specific clinical scenarios the 
DAPT duration can be shortened (< 12 months), 
extended (> 12 months), or modified (switching 
DAPT, DAPT de-escalation), and these decisions 
depend on individual clinical judgement being 
driven by the patient’s ischemic and bleeding risk, 
the occurrence of adverse events, comorbidities, 
co-medications, and availability of drugs [2]. Early 
discontinuation of P2Y12 receptor inhibitor therapy 
3 months after non-ST-elevation ACS should be 
considered in those who are at high bleeding risk 
(High Bleeding Risk according to Academic Bleed-
ing Consortium — ABC-HBR criteria or ≥ 25 score 
in PREdicting bleeding Complications In patients 
undergoing Stent implantation and subsEquent 
Dual AntiPlatelet Therapy — PRECISE-DAPT 
score) (class of recommendation IIa) [4]. Termina-
tion of treatment with ASA 3–6 months after ACS 
in patients treated with PCI with stent implantation 
should be considered, depending on the balance 
between bleeding and ischemic risk (class of rec-
ommendation IIa). Moreover, patients at very high 
bleeding risk, i.e. those who experienced bleeding 
episode within a month preceding the index ACS 
or those scheduled for surgical intervention in the 
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early future, may benefit from 1-month DAPT com-
prising ASA and clopidogrel, with the intention to 
continue monotherapy with clopidogrel afterwards 
(class of recommendation IIa) [4]. 
De-escalation of treatment with P2Y12 recep-
tor inhibitor (e.g. switch from prasugrel or ticagre-
lor to clopidogrel) may be considered in patients 
after ACS deemed unsuitable for potent platelet 
inhibition. De-escalation may be unguided, based 
solely on clinical judgment or guided by platelet 
function testing or CYP2C19 genotyping, depend-
ing on the patient’s risk profile and availability of 
respective assays (class of recommendation IIb) [4].
Dual antiplatelet treatment with ASA and 
P2Y12 receptor inhibitor (ticagrelor may be pre-
ferred over clopidogrel and prasugrel) or with a low 
dose of rivaroxaban is recommended in subjects 
without atrial fibrillation at high/moderate ischemic 
risk and low bleeding risk beyond 12 months post 
ACS (class of recommendation IIa/IIb) [4, 5].
Adherence to DAPT after ACS
Despite the numerous advantages of a po-
tent antiplatelet treatment, this therapy is also 
burdened with non-negligible side effects, greatly 
related to bleeding. These adverse effects quite of-
ten require medical attention or lead to discontinu-
ation of treatment. Of note, the rate of premature 
discontinuation of antiplatelet treatment in the 
landmark PLATO study was 23% of patients receiv-
ing ticagrelor and 22% treated with clopidogrel, 
which shows the magnitude of the problem [17]. 
Premature discontinuation of antiplatelet therapy, 
especially in invasively treated ACS patients, may 
lead to detrimental cardiovascular and thrombotic 
events, such as recurrent ACS or stent thrombosis 
[12, 17–21, 32, 33]. 
Premature discontinuation of treatment with 
ticagrelor in the PEGASUS-TIMI 54 was mostly 
driven by non-serious adverse events that oc-
curred primarily early after randomization, and it 
was more common in patients receiving standard 
compared with reduced ticagrelor maintenance 
dose [23–25]. Thus, better adherence to treat-
ment would be expected with low-dose ticagrelor 
in real-life practice. 
The ELECTRA-SIRIO 2 study
The ELECTRA-SIRIO 2 study was designed 
as a phase III, randomized, multicenter, double-
-blind, placebo-controlled, investigator-initiated 
clinical study with a 12-month follow-up (Clinical-
Trials.gov Identifier: NCT04718025; EudraCT 
number: 2020-005130-15). The study is aimed to 
test two ticagrelor-based de-escalation strategies 
versus standard treatment.
During the first month after ACS subjects 
from all three arms will receive a standard DAPT 
with ticagrelor 90 mg b.i.d and 100 mg ASA once 
daily. Patients assigned to the control group will 
continue this standard treatment for a total of 
12 months, while in both experimental arms after 
1 month the maintenance dose of ticagrelor will be 
reduced to 60 mg b.i.d. Then, 3 months after ACS, 
treatment with ASA will be terminated in one of the 
experimental arms. The primary safety composite 
endpoint of this study is the first occurrence of type 
2, 3, or 5 bleeding according to the BARC criteria, 
occurring during the first 12 months after ACS. 
The primary efficacy endpoint is the composite of 
time to death from any cause, first nonfatal MI, or 
first nonfatal stroke. 
Special care will be applied with regard to 
adherence to the study treatment (tablet count-
ing at follow-up visits and evaluation with use of 
the Adherence in Chronic Diseases Scale). The 
adherence to treatment is of vast importance 
because early termination of ticagrelor leaves the 
ACS patients in the monotherapy arm unprotected 
against ischemic consequences, such as recurrent 
ACS [34–40]. 
To increase adherence to treatment all patients 
will undergo continuous multilevel educational 
and motivational interventions according to 
the Multilevel Educational and Motivational In-
tervention in Patients After Myocardial Infarction 
(MEDMOTION) project, including assessment 
with the Readiness for Hospital Discharge after 
Myocardial Infarction Scale at the end of hospitali-
zation, and with the Functioning in Chronic Illness 
Scale during follow-ups [41–48].
Summary
To date, de-escalation of antiplatelet therapy 
in ACS patients based on lowering the dose of tica-
grelor with or without discontinuation of ASA has 
not been tested in a large randomized clinical trial.
Taking into account existing evidence, one 
would expect equal clinical efficacy of reduced and 
standard maintenance doses of ticagrelor already 
after 1 month post ACS based on their documented 
antiplatelet effects. The two antiplatelet de-escala-
tion strategies proposed in the ELECTRA-SIRIO 2 
study are expected to essentially decrease the 
incidence of clinically significant bleeding events 
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during the first year after ACS, without negative 
impact on the antithrombotic efficacy. In contrast 
to the platelet function testing-guided de-escalation 
strategy applied in the TROPICAL-ACS study [11], 
the strategy proposed in the ELECTRA-SIRIO 2 
study does not require a platelet reactivity as-
sessment, making this step-down approach more 
feasible for wide application in clinical practice.
Moreover, the quality of life in post-ACS 
patients on the tested regimen may increase due 
to lower incidence of dyspnea, an adverse effect 
typical for ticagrelor. This assumption is based on 
observations from the PEGASUS-TIMI 54 trial, 
where dyspnea occurred less frequently in patients 
who received the lower dose of ticagrelor compared 
with those treated with the standard dose (16% vs. 
19%) [23–25]. Thus, a lower number of patients 
are expected to permanently and prematurely 
discontinue ticagrelor. 
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